A unique prognostic role of the genetic duet of BRAF V600E and TERT promoter mutations
in papillary thyroid cancer (PTC) has been recently established, but the role of RAS mutation …

Background: Poorly differentiated thyroid cancer (PDTC) is a rare but clinically highly
significant entity because it accounts for most fatalities from non-anaplastic follicular cell …

Differentiated thyroid cancer (DTC) has become one of the most frequently diagnosed
malignancies, especially among women and young adults (Davies & Welch 2014). The …

Background Risk stratification for patients with differentiated thyroid cancer (DTC) is based
primarily on pathologic tumor characteristics. Accurate preoperative prognostication could …

Gene expression profiling shows that, by gene signature, the difference between BRAF-
positive and BRAF-negative PTC is so distinct that BRAF-positive cancer may be regarded …

Background: Similar to poorly differentiated thyroid carcinoma (PDTC), papillary thyroid
carcinoma with high-grade features (PTC HGF) demonstrates increased mitotic activity …

Simple Summary Tumor biomarkers are molecules at genetic or protein level, or certain
evaluable characteristics. These help in perfecting patient management. Over the past …

Although most papillary thyroid carcinomas (PTCs) have a good prognosis, a small but
certain fraction shows aggressive behavior. Therefore, a novel and well-performing …

Background: Papillary thyroid carcinoma (PTC) patients presenting with cervical lymph
nodes (LN) metastases (M) have a variable outcome. The objective of this study is to assess …

Context Modern management of differentiated thyroid cancer requires individualized care
plans that tailor the intensity of therapy and follow-up to the estimated risks of recurrence …